b'53102 Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream:1 Incyte Corporation, Presented at the Wilmington, DE,USA;American Academy Analysis of a US Payer Claims Database Carelon Research, 2 of Dermatology (AAD) Wilmington, DE, USAAnnual MeetingJinan Liu, MD, PhD, 1 * Karishma Desai, PhD, 2Chia-Chen* Presenting authorSan Diego, CATeng, MS, 2Daniel Sturm, PharmD, 1Grace Stockbower, March 812, 2024 MPH, 2Vincent Willey, PharmD 2Content provided by Incyte CorporationIntroduction Methods Atopic dermatitis (AD) is a chronic, heterogeneous, highly pruritic, relapsing Patients and Study Design inflammatory skin disease affecting ~4% of adults in the United States 1,2A retrospective observational study was conducted using claims data fromMany patients experience inadequate disease control with topical first-line the Healthcare Integrated Research Database (HIRD) therapies, such as topical corticosteroids (TCS), topical calcineurin inhibitors(TCI), and the phosphodiesterase-4 inhibitor (PDE-4i) crisaborole 3Patients with a first claim for ruxolitinib cream between October 2021 and July 2022 (index date; Figure 1) were included Ruxolitinib cream, a topically administered selective Janus kinase (JAK) Eligible individuals were 12 years old on the index date, with 1 pharmacy 4 1/JAK2 inhibitor approved in the United States in 2021,is an effective claim of ruxolitinib cream along with a medical claim with an AD diagnosis nonsteroidal monotherapy initially used twice daily continuously to reduce in the prior 6 months, and 6 months of continuous enrollment in a signs and symptoms of AD, and as-needed for longer-term disease control, healthcare plan beforeand after the index dateas shown in adults and adolescents with mild to moderate AD in two phase3 clinical studies: TRuEAD1/TRuE-AD2 (NCT03745638/NCT03745651) 5,6 Endpoints and Statistical AnalysisData before and after ruxolitinib cream use were summarized using descriptive statisticsFigure 1. Study DesignObjective To describe characteristics of patients with AD and treatment patterns before and after initiation of ruxolitinib cream using data from a large,nationwide US claims database'